Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other worldwide markets. (CLVS) traded up $0.08 during trading on Friday, reaching $68.00. About 76.15 million shares traded. Incyte Corporation (NASDAQ:INCY) has risen 72.84% since December 31, 2016 and is uptrending. It has outperformed by 266.01% the S&P500.
Capital Analysts LLC acquired a new stake in shares of Clovis Oncology in the third quarter valued at about $111,000. California Public Employees Retirement System now owns 33,384 shares of the biopharmaceutical company's stock worth $2,751,000 after acquiring an additional 3,484 shares during the last quarter. The institutional investor held 28,222 shares of the consumer services company at the end of 2017Q3, valued at $2.21M, up from 18,275 at the end of the previous reported quarter. Lucas Capital Management who had been investing in General Electric Co for a number of months, seems to be bullish on the $151.33 billion market cap company. The stock decreased 1.07% or $0.15 during the last trading session, reaching $13.82.
Clovis Oncology (NASDAQ:CLVS) last issued its earnings results on Wednesday, November 1st. It has underperformed by 2.87% the S&P500.
Since August 8, 2017, it had 2 insider buys, and 1 sale for $4.48 million activity. Insiders sold 13,500 shares of company stock valued at $907,200 in the last quarter. $131.11 million worth of Wal-Mart Stores, Inc. Corporation (NYSE:FNB) for 1.98 million shares.
Investors sentiment decreased to 0.82 in 2017 Q3. Its the same as in 2017Q2. Rhumbline Advisers raised its holdings in shares of Clovis Oncology by 5.3% during the second quarter. The biopharmaceutical company reported ($1.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.18) by ($0.06). Ubs Asset Mgmt Americas holds 373,745 shares. Meritage Portfolio Mgmt holds 13,206 shares or 0.1% of its portfolio. Palo Alto Investors Ltd Liability Corp holds 3.33M shares. Clovis Oncology Inc now has $3.33 billion valuation. Fred Alger Management invested in 828,407 shares or 0.32% of the stock. Rwwm holds 14.32% in Wal-Mart Stores, Inc. Oakbrook Invs Ltd Limited Liability Company holds 0.07% or 32,300 shares in its portfolio. Keybank Association Oh has invested 0% in F.N.B. Finally, Crestline Management LP acquired a new position in shares of Clovis Oncology in the 3rd quarter worth $1,319,000. Marketfield Asset Mngmt Llc owns 91,787 shares. State Street holds 1.99 million shares. Old Natl Bank In reported 15,736 shares. Dimensional Fund Advisors Limited Partnership stated it has 323,229 shares. The stock of Weyerhaeuser Company (NYSE:WY) earned "Hold" rating by Vertical Research on Tuesday, May 3. Therefore 38% are positive. Wal-Mart Stores Inc had 136 analyst reports since August 14, 2015 according to SRatingsIntel. Corporation (NYSE:FNB) on Thursday, July 20 with "Hold" rating. The stock of Wal-Mart Stores, Inc. Mizuho has "Neutral" rating and $23 target. WallachBeth Capital has "Hold" rating and $30 target. Stifel Nicolaus maintained Wal-Mart Stores, Inc. The firm earned "Hold" rating on Thursday, December 21 by Keefe Bruyette & Woods.More news: Vetr Lowers Activision Blizzard (NASDAQ:ATVI) to Sell
University Of Notre Dame Du Lac, which manages about $359.00M US Long portfolio, upped its stake in Achaogen Inc (NASDAQ:AKAO) by 51,786 shares to 155,654 shares, valued at $2.48 million in 2017Q3, according to the filing. It also reduced its holding in La Jolla Pharmaceutical Company (NASDAQ:LJPC) by 350,057 shares in the quarter, leaving it with 154,675 shares, and cut its stake in Immunogen Inc.
Since August 4, 2017, it had 0 buys, and 5 selling transactions for $2.32 million activity.
Equities analysts predict that Clovis Oncology, Inc.
In other Clovis Oncology news, Director Thorlef Spickschen sold 4,500 shares of the business's stock in a transaction on Friday, December 8th.
Longwood Capital Partners Llc, which manages about $558.01 million US Long portfolio, decreased its stake in Dbv Technologies S A (Call) by 98,765 shares to 9,000 shares, valued at $382,000 in 2017Q3, according to the filing. (NASDAQ:CLVS). Aperio Ltd Co, California-based fund reported 5,261 shares.More news: Where to watch the Outback Bowl
Investors sentiment decreased to 1.44 in Q3 2017. Its up 0.02, from 1.02 in 2017Q2. It turned negative, as 48 investors sold Clovis Oncology, Inc. shares while 49 reduced holdings.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Wells Fargo & Mn owns 273,094 shares or 0.01% of their United States portfolio. First Republic Inv accumulated 3,042 shares or 0% of the stock. Clovis Oncology, Inc. has a 52-week low of $39.83 and a 52-week high of $99.45. Clovis Oncology had a negative return on equity of 122.06% and a negative net margin of 947.47%. (NASDAQ:CLVS) for 512 shares. 14,861 are held by Brighton Jones Limited Liability Corp. Ellington Mngmt Grp Inc Limited Liability holds 0.04% or 6,300 shares. Td Asset Management invested in 24,485 shares.
Several other equities analysts have also commented on the company. (NASDAQ:CLVS). Great West Life Assurance Can has 0% invested in Clovis Oncology, Inc. (NASDAQ:CLVS). Chicago Equity Ptnrs Ltd Llc has invested 0.06% in Clovis Oncology, Inc. WallachBeth Capital downgraded Clovis Oncology, Inc. Sphera Funds Ltd has invested 1.86% in Clovis Oncology, Inc. (NASDAQ:CLVS) for 336,486 shares.
Clovis Oncology (NASDAQ:CLVS) was downgraded by research analysts at ValuEngine from a "hold" rating to a "sell" rating in a report released on Tuesday, December 5th. Therefore 50% are positive.
On average, analysts expect that Clovis Oncology will report full year sales of $20.02 million for the current financial year, with estimates ranging from $55.27 million to $62.47 million. The stock has "Neutral" rating by Chardan Capital Markets on Tuesday, December 20. The firm has "Buy" rating given on Friday, June 9 by Jefferies. Leerink Swann reaffirmed an "outperform" rating and issued a $90.00 target price (down previously from $107.00) on shares of Clovis Oncology in a research note on Wednesday, November 15th. The firm has "Buy" rating by J.P. Morgan given on Thursday, June 1. The rating was maintained by Piper Jaffray with "Neutral" on Monday, November 16. SunTrust maintained Clovis Oncology, Inc. (NASDAQ:CLVS) rating on Friday, September 23. The stock of Weyerhaeuser Company (NYSE:WY) earned "Buy" rating by Goldman Sachs on Thursday, September 22. The firm has "Neutral" rating given on Monday, January 25 by Mizuho. Finally, Morgan Stanley lowered their price objective on Clovis Oncology from $89.00 to $86.00 and set an "overweight" rating for the company in a research report on Thursday, November 2nd. The company was upgraded on Wednesday, September 21 by Credit Suisse. Bank of Montreal Can now owns 2,702 shares of the biopharmaceutical company's stock worth $253,000 after buying an additional 2,000 shares in the last quarter.More news: Proofpoint Inc (NASDAQ:PFPT) "Hold" Rating Has Just Been Reiterated by KeyBanc